REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaydale Regulatory News (HAYD)

Share Price Information for Haydale (HAYD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.46
Bid: 0.45
Ask: 0.47
Change: 0.019 (4.31%)
Spread: 0.02 (4.444%)
Open: 0.46
High: 0.46
Low: 0.46
Prev. Close: 0.441
HAYD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options & Surrender of Existing Options

26 Jan 2024 07:00

RNS Number : 9804A
Haydale Graphene Industries PLC
26 January 2024
 

 

For Release at 07:00

26 January 2024

 

Haydale Graphene Industries plc

 

("Haydale", "the Company" or the "Group")

 

Grant of share Options, Surrender of Existing Options and PDMR dealings

 

Grant of New Options

 

Haydale (AIM: HAYD), the global advanced materials group, announces that on 25 January 2024 the Company approved the grant of options under the 2020 EMI Scheme as amended to accommodate the terms of the New Options ("2020 EMI Scheme"), to certain directors of the Company ("Directors"), certain directors of the Company's subsidiaries ("Subsidiary Directors") and UK based staff of the Group, over an aggregate 151,500,000 ordinary shares of 0.1p ("New Options") each in the capital of the Company ("Ordinary Shares"), representing 8.4 per cent. of the Company's issued share capital.

 

Background to the New Options grants

 

The Company adopted the 2020 EMI Scheme to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. The options granted under the 2020 EMI Scheme have certain performance and / or length of tenure criteria as set out below. The New Options replace 55,650,000 current options held by existing option holders and extend options to include those who have more recently joined the Group. 

 

Terms of the New Options

 

All of the New Options have an exercise price of 0.5 pence per Ordinary Share (being a 2.0% premium to the closing mid-market price of the Company's Ordinary Shares on 25 January 2024, the day of the approval of the New Options grant). The proportion of the total New Option award to each individual is capable of vesting dependent on certain share price performance and / or length of tenure criteria (approved by the Remuneration Committee) as follows:

 

% of New Options subject to the Performance Condition

 

Performance Condition

50%

Vests and is exercisable in three equal tranches from the first, second and third anniversary of the date of Grant provided the Participant has remained in continuous employment (and has not served notice of resignation) with the Company and/or its Group. No other performance conditions.

15.0%

For a period of 15 consecutive dealing days, commencing after the date of Grant and ending on or before the 31 December 2025, the closing price of the Ordinary Shares exceeds 1.0p (one pence) per Ordinary Share.

15.0%

For a period of 15 consecutive dealing days, commencing after the date of Grant and ending on or before the 31 December 2026, the closing price of the Ordinary Shares exceeds 2.0p (two pence) per Ordinary Share.

20.0%

For a period of 15 consecutive dealing days, commencing after the date of Grant and ending on or before the 31 December 2027, the closing price of the Ordinary Shares exceeds 3.0p (three pence) per Ordinary Share.

 

All share options with a share price based performance condition can only be exercised on or after the third anniversary of grant. If the share price does not reach the target price by their respective dates, that portion of the award will lapse.

 

In respect of the New Option awards with no share price based performance conditions granted to each of Keith Broadbent (CEO) and Patrick Carter (CFO), these are subject to the further requirement that any resulting shares must be held for a minimum of 2 years from the date of option grant.

 

There are no other vesting criteria for the New Options.

 

Surrender of existing options

 

In January 2020, January 2022, November 2022 and April 2023, the Company granted options to acquire shares in the capital of the Company to certain employees and directors of the Company pursuant to the Scheme. It is a condition of the grant of New Options that the remaining rights to the 2020, 2022 and 2023 Options are surrendered for no consideration (the "Option Surrender").

 

The Options previously granted in 2020, January 2022, November 2022 and 2023 were priced at 2.25p, 6.25p, 2.25p and 2.25p, respectively. The board believe it is appropriate to issue new share options in replacement of the existing ones to reflect the Company's current share price to properly incentivise its employees, including its management.

 

 

Details of resultant holdings

 

Following the New Options grant and the Option Surrender, details of Options held by Directors, PDMRs and other employees of the Company and its subsidiaries, are as follows:

 

Director's name

and employing Group company

 

Number of 2020, 2022 and 2023 options surrendered

Number of New Options granted

Aggregate number of options

post grant

Current total beneficial holding of Ordinary Shares

 

 

Current holding as a % of Issued share capital

Keith Broadbent

(Haydale Graphene Industries Plc)

 

26,400,000

50,000,000

50,000,000

4,952,381

0.28%

Patrick Carter

(Haydale Graphene Industries Plc)

 

-

30,000,000

30,000,000

1,000,000

0.05%

David Davies

(Haydale Ltd)

 

4,400,000

10,000,000

10,000,000

50,671

0.00%

Mark Heycock

(Haydale Ltd)

2,650,000

10,000,000

10,000,000

-

-

John Mark Seymour

(Haydale Ltd)

2,650,000

10,000,000

10,000,000

-

-

Nicholas Weatherby

(Haydale Composite Solutions Ltd)

3,300,000

5,000,000

5,000,000

-

-

Other Employees

16,250,000

36,500,000

56,250,000*

n/a

n/a

Total:

55,650,000

151,500,000

171,250,000

6,003,052

0.33%

*Difference represents pre-existing grants to non-UK staff under SARs and non-qualifying EMIs.

 

 

 

Following the New Options grant and the Option Surrender, the Company's total number of Options under the 2020 EMI Scheme and under the Haydale Technologies, Inc Stock Appreciation Rights Plan 2020 outstanding as at the date of this announcement is 171,250,000 representing approximately 9.5% of the Company's existing issued share capital and 8.7% on a fully diluted basis including all outstanding warrants.

 

The number of Ordinary Shares currently in issue is 1,798,462,051 and it is this number that has been used to calculate the above percentage shareholdings.

 

 

For further information:

Haydale Graphene Industries plc

David Banks, Non-Executive Chair

Tel: +44 (0) 1269 842 946

 

www.haydale.com 

Cavendish Capital Markets Limited (Nominated Adviser & Broker)

 

Julian Blunt/Edward Whiley, Corporate Finance

Andrew Burdis, ECM

Tel: +44 (0) 20 7220 0500 

 

 

Notes to Editors

 

Haydale is a global technologies and materials group that facilitates the integration of graphene and other nanomaterials into the next generation of commercial technologies and industrial materials. With expertise in graphene, silicon carbide and other nanomaterials, Haydale is able to deliver improvements in electrical, thermal and mechanical properties, as well as toughness. Haydale has granted patents for its technologies in Europe, USA, Australia, Japan and China and operates from five sites in the UK, USA and the Far East.

 

For more information please visit: www.haydale.com

LinkedIn: Haydale-ltd

X: @haydalegraphene

 

 

The notification set out below is provided in accordance with the requirements of MAR.

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

 

1

 

Details of the person discharging managerial responsibilities/person closely associated

 

a.

Name

1. Keith Broadbent

2. Patrick Carter

3. David Davies

4. John Mark Seymour

5. Mark Heycock

6. Nicholas Weatherby

 

2

Reason for notification

 

a.

Position/Status

1. Chief Executive Officer of Haydale Graphene Industries Plc

2. Chief Financial Officer of Haydale Graphene Industries Plc

3. Director of Haydale Limited (PDMR)

4. Director of Haydale Limited (PDMR)

5. Director of Haydale Limited (PDMR)

6. Director of Haydale Composite Solutions Ltd (PDMR)

 

b.

Initial notification/

Amendment

Initial Notification

 

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a.

Name

Haydale Graphene Industries Plc

 

b.

LEI

213800KNULBQFF25IE72

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a.

Description of the financial instrument, type of instrumentIdentification Code

Options over Ordinary Shares of 0.1p each

 

n/a

 

b.

Nature of the transaction

Grant of options under the 2020 EMI Scheme with time vesting and share price performance conditions attached

 

c.

Price(s) and volume(s)

 

Exercise Price(s)

Volume(s)

 

 

 

 

1.

 £0.005

50,000,000

 

2.

£0.005

30,000,000

 

3.

£0.005

10,000,000

 

4.

£0.005

10,000,000

 

5.

£0.005

10,000,000

 

6.

£0.005

5,000,000

 

 

 

d.

Aggregated information

- Aggregated Volume

- Price

 

See above

 

e.

Date of the transaction

25 January 2024

 

f.

Place of the transaction

Outside a trading venue

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHPPUPWGUPCGBA
Date   Source Headline
23rd Dec 20167:00 amRNSIssue of Shares
15th Dec 20163:00 pmRNSResult of AGM
15th Dec 20167:00 amRNSAGM Statement
28th Nov 20167:00 amRNSAgreement with Huntsman Advanced Materials
22nd Nov 20167:00 amRNSAnnual Financial Report
19th Oct 20167:00 amRNSPDMR Dealings
18th Oct 20167:00 amRNSPDMR Dealings
17th Oct 20167:00 amRNSGrant of Options
13th Oct 20167:00 amRNSDistribution Agreement
13th Oct 20167:00 amRNSPDMR Dealings
11th Oct 20167:00 amRNSResult of Open Offer and Total Voting Rights
28th Sep 20167:00 amRNSContract Extension
23rd Sep 201610:57 amRNSResult of Placing
23rd Sep 20167:01 amRNSFinal Results
23rd Sep 20167:00 amRNSProposed Acquisition and Fundraise
9th Sep 20164:05 pmRNSCompletion of Innophene Acquisition
26th Aug 20167:00 amRNSDirector/PDMR Shareholding
25th Aug 20167:00 amRNSAcquisition and Issue of Equity
11th Aug 20167:00 amRNSGraphene Enhanced PLA Filaments for 3D Printing
8th Aug 20167:00 amRNSHaydale Funds New Professorial Chair Within WCPC
29th Jul 20167:00 amRNSBoard Change
7th Jun 201610:42 amRNSGrant of Warrants
26th May 20167:00 amRNSAgreement with Flowtite Technology AS
20th May 20163:27 pmRNSDirector Dealing
20th May 20167:00 amRNSGrant of Options
18th May 20167:00 amRNSReactor Supply and Collaboration Agreement
9th May 20167:00 amRNSInvestor Open Day
25th Apr 20164:40 pmRNSHolding(s) in Company
7th Apr 201611:28 amRNSCorrection: Joint Development & Supply Agreement
7th Apr 20167:00 amRNSJoint Development and Supply Agreement
22nd Mar 20167:00 amRNSHalf Yearly Report
14th Mar 20167:00 amRNSGraphene Enhanced Composite Products Launched
8th Mar 201611:12 amRNSNotice of Results
16th Feb 20167:00 amRNSGrant Awards
4th Feb 20167:00 amRNSHaydale Commission Composite Pipe Testing Facility
3rd Feb 20167:00 amRNSAcquisition of Rights and Grant of Warrants
3rd Dec 201511:58 amRNSResult of AGM
1st Dec 201512:05 pmRNSDirector Dealing
26th Nov 20157:00 amRNSHolding(s) in Company
25th Nov 20157:00 amRNSHolding(s) in Company
23rd Nov 201510:50 amRNSResults of General Meeting
20th Nov 20151:14 pmRNSResult of Open Offer
17th Nov 20157:00 amRNSGrant Awards
10th Nov 201511:32 amRNSNotice of AGM
6th Nov 20154:45 pmRNSPosting of Open Offer Application Forms
2nd Nov 201512:50 pmRNSDirector/PDMR Shareholding
2nd Nov 20157:01 amRNSIssue of Equity
2nd Nov 20157:00 amRNSFinal Results
14th Oct 20157:00 amRNSEuropean Patent Grant
1st Oct 20157:00 amRNSAgreement with Scott Bader Company Ltd

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.